Corcept Therapeutics

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Corcept Therapeutics reports robust earnings, navigates legal challenges for growth

Corcept Therapeutics demonstrated strong financial performance, stability, and strategic investments in key areas of its business.
While facing legal challenges and adapting to industry changes, the company capitalized on opportunities for growth and innovation.
Overall, Corcept's focus on clinical advancements and strategic investments positions it well for future success and expansion in the healthcare sector.

Corcept Therapeutics reports revenue growth, legal battles with Teva

Corcept Therapeutics delivered strong Q1 performance with revenue growth and a robust financial position.
The company faces challenges in managing expenses, legal battles, and sustaining R&D investments.
Opportunities lie in sales force expansion, clinical trials, and upcoming studies for growth and innovation.
Overall, Corcept's strategic focus on growth and legal defense positions it for future success in the market.

Corcept Therapeutics reports robust Q2 earnings and expands treatment reach

Corcept Therapeutics delivered strong financial performance, raised revenue guidance, and showcased progress in clinical development programs.
While facing legal challenges and market expansion complexities, the company's proactive strategies and positive trial results position it well for future growth.
Opportunities in partnerships, physician engagement, and broadening disease applications underscore Corcept's potential for continued success and impact in the healthcare industry.

Corcept Therapeutics excels in Q3, eyes growth in new markets

Corcept Therapeutics demonstrated robust financials, strategic wins in legal battles, and a focus on market expansion and product innovation.
While facing challenges in maintaining competitive positioning and navigating regulatory landscapes, the company is poised for growth.
With a strong performance in Q3 2023 and promising opportunities ahead, Corcept is well-positioned to capitalize on its strengths and drive future success.

Corcept Therapeutics reports robust Q4 revenue and diversifies pipeline

Corcept Therapeutics demonstrated strong financial performance in Q4 2023 with revenue growth and profitability.
The company's ongoing research and diversified pipeline position it well for future growth.
Challenges include legal disputes and market competition, but strategic planning and label expansions offer opportunities.
Overall, Corcept's financial stability, confidence in growth, and focus on treatment efficacy are key takeaways.

Corcept Therapeutics reports robust Q1 performance and eyes market expansion

Corcept Therapeutics delivered strong financial performance in Q1 2024, with revenue growth, increased net income, and raised revenue guidance.
The company's focus on innovative treatments for hypercortisolism and various cancers positions it well for future growth and market expansion.
While facing challenges like legal battles and operational complexity, Corcept remains optimistic about its pipeline and market potential.

Corcept Therapeutics reports strong Q2 performance amidst pipeline advancements

Corcept Therapeutics demonstrated robust financial performance and commercial growth in Q2 2024, supported by a strong cash position.
The company's pipeline strength was evident through positive study results for relacorilant and ongoing trials in various medical conditions.
While facing legal challenges and NDA submission delays, Corcept has opportunities to leverage its pipeline and market strategies for future success.

Corcept Therapeutics reports strong Q3 earnings and advances pipeline

Corcept Therapeutics delivered robust financial results, showing substantial revenue growth and profitability in Q3 2024. The company's pipeline progress and expanded revenue guidance underscore its strong market position and growth potential.
While facing legal challenges and complexities in clinical development, Corcept's strategic initiatives in multiple therapeutic areas and combination therapies position it well to capitalize on market opportunities and drive future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company. It engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Catalyst Pharmaceuticals

Exelixis

Ligand Pharmaceuticals

United Therapeutics

The top five biotech stocks today have several commonalities. Among them are strong ratings.

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its Phase 3 long-term, open-label extension study of relacorilant to treat patients with endogenous hypercortisolism (Cushing's syndrome) at the WCIRDC. The results from this.

Corcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym® in patients with hypercortisolism (Cushing's syn.

Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes

The phase II DAZALS study evaluating Corcept's dazucorilant in patients with amyotrophic lateral sclerosis fails to meet the primary goal.

CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease.

Corcept Therapeutics' ALS drug fails in mid-stage trial

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol, today announced results from the DAZALS study, a randomized, double-blind, placebo-controlled, Phase 2 trial evaluating two doses (150 mg and 300 mg) of its proprietary selective cortisol modulator.

Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock

Corcept (CORT) could produce exceptional returns because of its solid growth attributes.

Corcept (CORT) is an Incredible Growth Stock: 3 Reasons Why

The consensus price target hints at a 26.1% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 26.05% Upside in Corcept (CORT): Can the Stock Really Move This High?

Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

What Makes Corcept (CORT) a Good Fit for 'Trend Investing'

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue?

Corcept Therapeutics specializes in cortisol-modulating drugs, with Korlym targeting Cushing Syndrome and a promising pipeline, including Relacorilant, for diabetes and ovarian cancer. CORT's robust financials, strong profitability, and near-monopolistic position in a niche market underscore its investment potential despite legal risks and reliance on a single product. The company's innovative pipeline, especially Relacorilant, could significantly expand its market reach and diversify revenue streams, driving strong future growth.

Corcept Therapeutics: A Most Promising And Compelling Biotech

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term

CORT's Cushing's syndrome drug, Korlym, is driving revenues. The NDA for relacorilant in Cushing's syndrome will be filed shortly.

Corcept Shares Rise More Than 60% in Three Months: Here's Why

Corcept (CORT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Growth Investors Will Love Corcept (CORT)

The average of price targets set by Wall Street analysts indicates a potential upside of 37.9% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet

Corcept (CORT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Corcept (CORT) is on the Move, Here's Why the Trend Could be Sustainable

Larimar Therapeutics Inc

Madrigal Pharmaceuticals

Theravance Biopharma

Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.

5 Small Drug Stocks to Buy as Trump Gets Re-Elected

Investors should invest in CORT right now as the stock is doing extremely well in 2024 and its prospects look even brighter.

Corcept Therapeutics Stock Surges 61% in 2024: A Must Buy?

Here is Why Growth Investors Should Buy Corcept (CORT) Now

Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Corcept (CORT) Upgraded to Strong Buy: Here's Why

Quad/Graphics

Zebra Technologies

CORT, ZBRA and QUAD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 5, 2024.

Best Momentum Stocks to Buy for November 5th

Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out?

American Assets

Comerica

AAT, QUAD, CORT, CMA and ADT have been added to the Zacks Rank #1 (Strong Buy) List on November 5, 2024.

News for Corcept Therapeutics Stock (CORT)